[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607719":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":40,"responsibleParty":59,"collaborators":11,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":11,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":70,"enrollmentInfo":71,"targetDuration":11,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":11,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Rohto Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Mesenchymal stem cell","EXPERIMENTAL",null,[13],"Biological: Mesenchymal stem cell",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Biological: Placebo",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"BIOLOGICAL","ADR-002K administration",[9],{"type":21,"name":15,"description":15,"armGroupLabels":25,"otherNames":11},[15],[27],{"name":28,"affiliation":29,"role":30},"Shigeru Miyagawa, profesor","Osaka University","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Sumito Okawa, Study Director","CONTACT","81-3-6832-6014","R-regenerative_medicine@rohto.co.jp",{"name":38,"role":34,"phone":39,"phoneExt":11,"email":36},"Toshiyuki Osawa","81-6-6447-8610",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The University of Osaka Hospital","RECRUITING","Osaka","Suita","5650871","Japan","JP",{"type":50,"coordinates":51},"Point",[52,53],135.50107,34.69379,{"lat":53,"lon":52},[56],{"name":11,"role":34,"phone":57,"phoneExt":11,"email":58},"081-6-6879-5111","jim-chiken@hp-crc.med.osaka-u.ac.jp",{"type":60,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100607719","phase-2-exploratory-study-of-adr-002k-for-heart-failure-patients-with-ischemic-heart-disease-who-undergo-cabg-100607719",false,"NCT07192211","Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG","Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo Coronary Artery Bypass Surgery","Inclusion Criteria:\n\n1. Patients clinically diagnosed with chronic heart failure due to ischemic heart disease who undergo CABG\n2. Patients with an LVEF of less than 40% as determined by the cardiac ultrasound at the screening examination.\n3. Others\n\nExclusion Criteria:\n\n1. Patients who have a combination of cardiovascular disease such as severe organic valvular disease.\n2. Patients who have developed acute coronary syndrome within 3 months prior to obtaining consent.\n3. Others","ALL","18 Years","80 Years",{"count":72,"type":73},50,"ESTIMATED","INTERVENTIONAL",[76],"PHASE2","ADR-002K is administered to heart failure patients with ischemic heart disease who undergo coronary artery bypass surgery (CABG) to investigate its efficacy and safety.",[79],"Ischemic Heart Disease","2026-06-07",{"date":82,"type":83},"2026-06-09","ACTUAL",{"date":85,"type":83},"2026-04-28",{"date":87,"type":73},"2029-03-31",{"name":5,"class":6},1]